Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF): 2015-2025

Historic Depreciation & Amortization (CF) for Cartesian Therapeutics (RNAC) over the last 11 years, with Sep 2025 value amounting to $606,000.

  • Cartesian Therapeutics' Depreciation & Amortization (CF) rose 111.89% to $606,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 202.77%. This contributed to the annual value of $1.2 million for FY2024, which is 36.54% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Depreciation & Amortization (CF) is $606,000, which was up 2.89% from $589,000 recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q1 2025 and a low of $176,000 during Q2 2023.
  • Its 3-year average for Depreciation & Amortization (CF) is $395,000, with a median of $272,000 in 2023.
  • Per our database at Business Quant, Cartesian Therapeutics' Depreciation & Amortization (CF) tumbled by 48.99% in 2023 and then soared by 531.69% in 2025.
  • Cartesian Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $401,000 in 2021, then tumbled by 39.90% to $241,000 in 2022, then climbed by 12.86% to $272,000 in 2023, then surged by 78.68% to $486,000 in 2024, then surged by 111.89% to $606,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $606,000 for Q3 2025, versus $589,000 for Q2 2025 and $1.2 million for Q1 2025.